Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!
Bob Apple has been the CEO of Antares Pharma, Inc. (NASDAQ:ATRS) since 2016. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we'll look at a snap shot of the business growth. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels.
How Does Bob Apple's Compensation Compare With Similar Sized Companies?
According to our data, Antares Pharma, Inc. has a market capitalization of US$475m, and pays its CEO total annual compensation worth US$3.7m. (This figure is for the year to December 2017). While we always look at total compensation first, we note that the salary component is less, at US$528k. When we examined a selection of companies with market caps ranging from US$200m to US$800m, we found the median CEO total compensation was US$1.5m.
Thus we can conclude that Bob Apple receives more in total compensation than the median of a group of companies in the same market, and of similar size to Antares Pharma, Inc.. However, this doesn't necessarily mean the pay is too high. We can get a better idea of how generous the pay is by looking at the performance of the underlying business.
You can see a visual representation of the CEO compensation at Antares Pharma, below.
Is Antares Pharma, Inc. Growing?
Antares Pharma, Inc. has increased its earnings per share (EPS) by an average of 22% a year, over the last three years (using a line of best fit). It achieved revenue growth of 17% over the last year.
This shows that the company has improved itself over the last few years. Good news for shareholders. It's a real positive to see this sort of growth in a single year. That suggests a healthy and growing business. You might want to check this free visual report on analyst forecasts for future earnings.
Has Antares Pharma, Inc. Been A Good Investment?
Boasting a total shareholder return of 222% over three years, Antares Pharma, Inc. has done well by shareholders. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.
We examined the amount Antares Pharma, Inc. pays its CEO, and compared it to the amount paid by similar sized companies. We found that it pays well over the median amount paid in the benchmark group.
However, the earnings per share growth over three years is certainly impressive. On top of that, in the same period, returns to shareholders have been great. As a result of this good performance, the CEO remuneration may well be quite reasonable. If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Antares Pharma.
Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies, that have HIGH return on equity and low debt.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.